CN104884081A - 免疫原性组合物 - Google Patents

免疫原性组合物 Download PDF

Info

Publication number
CN104884081A
CN104884081A CN201380063596.3A CN201380063596A CN104884081A CN 104884081 A CN104884081 A CN 104884081A CN 201380063596 A CN201380063596 A CN 201380063596A CN 104884081 A CN104884081 A CN 104884081A
Authority
CN
China
Prior art keywords
seq
toxin
immunogenic composition
immunogenic
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380063596.3A
Other languages
English (en)
Chinese (zh)
Inventor
D.布特里奥
S.M.J.V.格迈因
H.瓦莱马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to CN202011473000.5A priority Critical patent/CN112807422A/zh
Publication of CN104884081A publication Critical patent/CN104884081A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201380063596.3A 2012-12-05 2013-12-03 免疫原性组合物 Pending CN104884081A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011473000.5A CN112807422A (zh) 2012-12-05 2013-12-03 免疫原性组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1221875.6 2012-12-05
GB201221875 2012-12-05
PCT/EP2013/075405 WO2014086787A1 (en) 2012-12-05 2013-12-03 Immunogenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202011473000.5A Division CN112807422A (zh) 2012-12-05 2013-12-03 免疫原性组合物

Publications (1)

Publication Number Publication Date
CN104884081A true CN104884081A (zh) 2015-09-02

Family

ID=49724573

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380063596.3A Pending CN104884081A (zh) 2012-12-05 2013-12-03 免疫原性组合物
CN202011473000.5A Pending CN112807422A (zh) 2012-12-05 2013-12-03 免疫原性组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202011473000.5A Pending CN112807422A (zh) 2012-12-05 2013-12-03 免疫原性组合物

Country Status (22)

Country Link
US (2) US9694064B2 (enExample)
EP (2) EP2928489B1 (enExample)
JP (2) JP6290918B2 (enExample)
CN (2) CN104884081A (enExample)
AR (1) AR093712A1 (enExample)
AU (1) AU2013354186A1 (enExample)
BR (1) BR112015012841B1 (enExample)
CA (1) CA2893435C (enExample)
CY (1) CY1121560T1 (enExample)
DK (2) DK3513806T5 (enExample)
ES (2) ES2939307T3 (enExample)
FI (1) FI3513806T3 (enExample)
HR (2) HRP20190711T1 (enExample)
HU (2) HUE061273T2 (enExample)
LT (2) LT3513806T (enExample)
PL (2) PL2928489T3 (enExample)
PT (2) PT3513806T (enExample)
SG (1) SG11201503861UA (enExample)
SI (2) SI2928489T1 (enExample)
TR (1) TR201905272T4 (enExample)
WO (1) WO2014086787A1 (enExample)
ZA (1) ZA201503927B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486515B2 (en) * 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
CN103619871B (zh) 2011-04-22 2016-12-14 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
ES2939307T3 (es) * 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa Composición inmunogénica
WO2015197737A1 (en) * 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
US10533036B2 (en) 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3433264A4 (en) 2016-03-21 2019-08-28 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR INHIBITING WNT SIGNALING
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018170238A2 (en) * 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
WO2019143552A1 (en) 2018-01-16 2019-07-25 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
JP7637988B2 (ja) * 2019-05-21 2025-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クロストリジウム・ディフィシルのワクチン組成物
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2024127215A2 (en) * 2022-12-13 2024-06-20 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068907A2 (en) * 2005-12-13 2007-06-21 Glaxosmithkline Biologicals Sa Vaccine compositions comprising a saponin adjuvant
WO2008043774A1 (en) * 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
CN101330924A (zh) * 2005-12-13 2008-12-24 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物
WO2010017383A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
CN102099052A (zh) * 2008-04-16 2011-06-15 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2012028741A1 (en) * 2010-09-03 2012-03-08 Intercell Ag Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU709586B2 (en) 1994-10-24 1999-09-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
AU2008299885C1 (en) 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
CN107098977A (zh) * 2011-05-27 2017-08-29 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
ES2939307T3 (es) * 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa Composición inmunogénica

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068907A2 (en) * 2005-12-13 2007-06-21 Glaxosmithkline Biologicals Sa Vaccine compositions comprising a saponin adjuvant
CN101330924A (zh) * 2005-12-13 2008-12-24 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物
WO2008043774A1 (en) * 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
CN102099052A (zh) * 2008-04-16 2011-06-15 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2010017383A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2012028741A1 (en) * 2010-09-03 2012-03-08 Intercell Ag Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARCON NATHALIE ET AL: "Development and evaluation of AS03,and adjuvant system containing[alpha]-tocopherol and squalene in an oil-in-water emulsion", 《EXPERT REVIEW OF VACCINES》 *
GINAMARIE FOGLIA ET AL: "Clostridium difficile:development of a novel candidate vaccine", 《VACCINE》 *
H.WANG ET AL: "A chimeric toxin vaccine protects against primary and recurrent clostridium difficile infection", 《INFECTION AND IMMUNITY》 *
SANDRA MOREL ET AL: "Adjuvant system AS03 containing-tocopherol modulates innate immune response and leads to improved adaptive immunity", 《VACCINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用

Also Published As

Publication number Publication date
JP2018104446A (ja) 2018-07-05
ES2939307T3 (es) 2023-04-20
HRP20230359T1 (hr) 2023-06-09
SI2928489T1 (sl) 2019-05-31
SI3513806T1 (sl) 2023-04-28
DK3513806T5 (da) 2024-09-02
US9694064B2 (en) 2017-07-04
PL2928489T3 (pl) 2019-07-31
AR093712A1 (es) 2015-06-17
US20150313984A1 (en) 2015-11-05
PT3513806T (pt) 2023-03-02
BR112015012841B1 (pt) 2022-05-03
PL3513806T3 (pl) 2023-05-15
EP3513806A1 (en) 2019-07-24
FI3513806T3 (fi) 2023-04-26
US10130694B2 (en) 2018-11-20
JP6626521B2 (ja) 2019-12-25
JP6290918B2 (ja) 2018-03-07
HUE061273T2 (hu) 2023-06-28
HUE043091T2 (hu) 2019-08-28
CA2893435C (en) 2024-11-12
WO2014086787A1 (en) 2014-06-12
LT3513806T (lt) 2023-04-11
JP2016502551A (ja) 2016-01-28
EP2928489B1 (en) 2019-02-27
ZA201503927B (en) 2017-11-29
PT2928489T (pt) 2019-05-28
EP2928489A1 (en) 2015-10-14
CN112807422A (zh) 2021-05-18
DK2928489T3 (en) 2019-04-23
HRP20190711T1 (hr) 2019-05-31
BR112015012841A2 (pt) 2017-09-26
CY1121560T1 (el) 2020-05-29
US20170340719A1 (en) 2017-11-30
CA2893435A1 (en) 2014-06-12
ES2721930T3 (es) 2019-08-06
EP3513806B1 (en) 2023-01-25
AU2013354186A1 (en) 2014-06-12
TR201905272T4 (tr) 2019-05-21
DK3513806T3 (da) 2023-02-27
SG11201503861UA (en) 2015-06-29
LT2928489T (lt) 2019-04-10

Similar Documents

Publication Publication Date Title
JP6626521B2 (ja) 免疫原性組成物
US10377816B2 (en) Nucleotide sequences, vectors and host cells
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
JP2021035950A (ja) 変異体ブドウ球菌抗原
JP2015528457A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
Lu et al. Systemic and mucosal immune responses elicited by intranasal immunization with a pneumococcal bacterium-like particle-based vaccine displaying pneumolysin mutant Plym2
US8916162B2 (en) Botulinum neurotoxin antigenic compositions and methods
CN106536544A (zh) 艰难梭菌免疫原性组合物
Gebara et al. Adjuvant and immunogenic activities of the 73 kDa N-terminal α-domain of BrkA autotransporter and Cpn60/60 kDa chaperonin of Bordetella pertussis

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150902